About Odile

Odile Smith serves as Vice President and Site Head for Bristol Myers Squibb’s Devens, Massachusetts campus—one of the company’s most advanced and strategically important manufacturing hubs. She oversees a rapidly expanding operation comprising a large-scale commercial biologics facility, a single-use biologics clinical and launch facility, and a state-of-the-art cell therapy facility producing CAR T cell therapies for cancer patients. Her leadership spans all site operations, including operational excellence, cost stewardship, digital transformation, engineering, EHS, and the full suite of campus amenities supporting more than 1,600 employees.

Odile is known for building high-performing, people-focused organizations grounded in trust, accountability, and continuous improvement. She plays a central role in shaping an inclusive culture that empowers employees to innovate, strengthen their technical capabilities, and take on diverse experiences to advance their careers. She also serves as a senior representative for BMS across the region, engaging local officials, government agencies, and community organizations to strengthen the company’s presence within the Massachusetts life sciences ecosystem.

Under her leadership, Devens has undergone significant growth and transformation. The 2021 ribbon cutting of the new cell therapy facility marked a major milestone in the site’s evolution from a single-modality biologics operation to a dynamic, multi-modality campus supporting commercial supply, clinical development, and next-generation manufacturing capabilities. In recognition of her contributions, Odile received the Worcester Business Journal’s Outstanding Women in Business Award in 2022.

Odile joined BMS in 2021 from Sanofi Pasteur, where she spent 17 years in roles of increasing responsibility across manufacturing, technology, operations, and capital project leadership. As Head of Biologics Manufacturing, she led a 700-person organization across multiple licensed production buildings and support groups supplying drug substance for global viral and bacterial vaccines. Earlier, she served as Senior Director of Manufacturing Technology, responsible for late-phase CMC development, industrialization, validation, and technical support for U.S. and international markets. She also held key leadership roles as CMC leader for the C. difficile vaccine program, director of manufacturing technology, project director, project leader, and operations manager.

Prior to Sanofi, Odile held operations and technical leadership positions with Roche and Rohm & Haas (Dow Chemical), where she built foundational expertise in production operations, process engineering, quality systems, automation, and team leadership across sites in both the United States and France.

A native of France, Odile holds a PhD in Medicinal Chemistry from the University Louis Pasteur in Strasbourg and a bachelor’s degree in Chemical Engineering from the Ecole Européenne des Hautes Études des Industries Chimiques de Strasbourg.